Brief: Windtree Therapeutics Initiates Seismic C Study Of Istaroxime In SCAI Stage C Cardiogenic Shock For Planned Completion Of Phase 2b And Transition To Phase 3
30/10/2024 13:11
Oct 30 (Reuters) - Windtree Therapeutics Inc WINT.O :
* WINDTREE THERAPEUTICS INITIATES SEISMIC C STUDY OF
ISTAROXIME IN
SCAI STAGE C CARDIOGENIC SHOCK FOR PLANNED COMPLETION OF PHASE
2B AND TRANSITION TO PHASE 3
Source text: ID:nGNX4tYjyr
Further company coverage: WINT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Windtree Therapeutics
See all newsBrief: Windtree Therapeutics Announces It Has Signed A Letter Of Intent To Acquire Commloan
Brief: Windtree Therapeutics Announces It May Receive License Agreement Payments From Its Licensee For Renewed Acute Pulmonary Development By The Licensee
Brief: Windtree Therapeutics Stockholders Approve Key Proposals For Revenue And Profit Generation At The Special Stockholder Meeting
Brief: Windtree Therapeutics Terminates Seismic-C Clinical Study At 20 Enrollments - SEC Filing
Brief: Windtree Therapeutics Inc - Announces Interim Analysis Of Istaroxime Phase 2 Study